How I Treat Advanced Head Neck Cancer

Somnath Roy1, Joydeep Ghosh1 Sandip Ganguly1

1 Department of Medical Oncology, Tata Medical Center, Newtown, Kolkata, West Bengal, India

Address for correspondence Sandip Ganguly, MD, DM (Medical Oncology), Consultant, Tata Medical Center, Department of Medical Oncology, 14 Mar EW Arterial Road, Newtown, Kolkata, West Bengal, India Pin 7000160 (e-mail: dr.babumashai@gmail.com).

Introduction

In India, head and neck cancer including all sites is the most common cancer in terms of incidence and mortality among both sexes combined as per GLOBOCAN 2018, with lip and oral cavity being the most common site.1 Squamous cell cancer of head neck (HNSCC) constitutes the majority of all head and neck malignancies.2 Most of the patients present in the advanced stage.3 Even localized HNSCC are notorious for high rates of recurrence in spite of curative modalities of treatment.4 Treatment for advanced recurrent HNSCC is palliative systemic therapy provided that patients have a good Eastern Cooperative Oncology Group (ECOG) performance score (PS) with normal organ function.

Platinum-based systemic therapy is the standard of treatment in advanced metastatic HNSCC over a long period of time. Over time, antiepidermal growth factor receptor (EGFR) monoclonal antibody like cetuximab showed additional survival benefit over platinum-based therapy.5 Recently, immune-checkpoint inhibitors (IOs) have been found to benefit both in first- and second-line settings as a single agent or in combination with platinum-based therapy.6 Last but not the least, metronomic therapy has shown a survival benefit in recurrent metastatic settings.7 In addition to systemic therapy, supportive care in controlling the symptoms is absolutely essential in the management of advanced HNSCC.4

India is a low middle-income country with a per capita income of Rs 11,254/- only. Majority of the people are not covered by health insurance.8 The cost of modern therapies like cetuximab and IOs are beyond the reach of most people from India. Hence, the treatment of any cancer including metastatic HNSCC has to be tailored based on the financial affordability of the patients and it should be used as an important factor to decide the systemic therapy.

Case 1

A 50-year-old male with a history of tobacco consumption presented with an ulcerated lesion over the lateral border of the tongue for the last 4 months. On clinical examination, there was an ulcerated lesion measuring 4 × 4 cm with matted cervical lymphadenopathy. Biopsy of the lesion revealed a squamous cell carcinoma. Staging work-up revealed multiple lung metastases. His ECOG PS was 1 and his organ functions were within normal limits. The patient could not afford the targeted therapy and immune checkpoint inhibition as his monthly salary was Rs 15,000/- only. How to treat the patient?

The above patient was a case of de novo metastatic HNSCC. As the patient could not afford targeted therapies including immune checkpoint inhibitors, the patient could be treated with systemic therapy only. Historically, methotrexate alone was the standard systemic in recurrent metastatic HNSCC with a response rate of around 30%.9 Phase II trials have shown that cisplatin alone had a similar response rate to single-agent methotrexate with increased toxicity.9 Carboplatin is a platinum analog with a better toxicity profile in contrast to cisplatin. Carboplatin has also shown a response rate of around 24% in the metastatic HNSCC with greater ease in administering the drug.9

Based on the encouraging response rates, a trial was made to use combination therapy in this setting. Phase III Southwest Oncology Group study was planned to see the effect of combination chemotherapy over single-agent methotrexate with the primary objective being to see response rate of doublet therapy over a single agent. It was a three-armed study. The study arms were a combination of cisplatin and 5 fluorouracil (5FU) and carboplatin and 5 FU with single-agent methotrexate being the control arm. The overall response rates were 32, 21, and 10%, respectively, with the

ISSN 0971-5851.

© 2022. Indian Society of Medical and Paediatric Oncology. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
difference in response rate between cisplatin and 5FU being statistically significant than single-agent methotrexate.\textsuperscript{11} Overall survival (OS) among the three arms were similar.

There was increased grade 3 and higher hematological toxicity along with renal toxicity in the cisplatin and 5FU arm. Based on this study, cisplatin and 5FU became the standard of therapy in metastatic HNSCC.

There was increased toxicity in the cisplatin and 5FU arm and it was attributed to the usage of 5FU. An attempt was made to replace 5FU with paclitaxel. Phase III trial (E1395) was planned to compare cisplatin and 5FU with a combination of cisplatin and paclitaxel.\textsuperscript{12} The response rate and OS in both the arms were comparable with less gastrointestinal and hematological toxicity in the paclitaxel arm.

Docetaxel was also used in combination with cisplatin in many phase II studies and they have shown response rates varying between 30 and 50%.\textsuperscript{13,14} No phase III trial has been conducted with this combination.

Pemetrexed—an antifolate analog—has been also tried in combination with cisplatin in advanced HNSCC. Phase III study was done to compare the efficacy of cisplatin pemetrexed over cisplatin alone. There was no added survival benefit with the doublet regime over single agent. But in post planned subset analysis, it was found that there was survival benefit in patients with oropharyngeal primary and with ECOG PS 0–1.\textsuperscript{15}

In summary, combination chemotherapy has shown only improved response rate over single-agent therapy at an added cost of increased toxicity. None of the studies have shown OS benefit with combination therapy.\textsuperscript{10,16}

**Case 2**

**A 45-year-old female with a history of tobacco consumption presented with an ulcerated lesion over the buccal mucosa for the last 4 months.** On clinical examination, there was an ulcerated lesion measuring 4 × 4 cm and with matted cervical lymphadenopathy. Biopsy of the lesion showed squamous cell carcinoma. Staging workup revealed multiple lung metastases. Her ECOG PS was 1 and her organ functions were within normal limits. **How to treat the patient?**

Treatment benefit with systemic chemotherapy alone is modest in metastatic HNSCC. Targeted therapies including monoclonal antibodies and very recently immunotherapies have shown improved survival benefit when compared with systemic therapy alone.

Tumor cells from HNSCC do express high levels of EGFR and it is associated with poor prognosis.\textsuperscript{17,18} Cetuximab is a chimeric monoclonal antibody that binds to EGFR receptor and causes cell death through antibody dependent cytotoxicity. It has been found to have a synergistic effect in combination with chemotherapeutic agents.\textsuperscript{19,20}

In the landmark phase III EXTREME trial, cetuximab was used in combination with cisplatin 5FU and it was compared with the chemotherapy arm.\textsuperscript{5} It was found that there is an absolute OS advantage of 2.8 months (hazard ratio [HR]: 0.8; 95% confidence interval [CI]: 0.64–0.99; \( p = 0.04 \)) in the cetuximab arm. There was a higher incidence of hypomagnesemia, skin rash, infusion reaction, and sepsis related to cetuximab.

In view of concerns regarding toxicity with cisplatin 5FU, cetuximab has been used with taxol and cisplatin. In the TPEXtreme trial, cetuximab was used with either cisplatin 5FU or cisplatin docetaxel.\textsuperscript{21} There was a similar OS in both the arms with less toxicity and reduced rates of discontinuation in the taxane combination group, thus making another alternative regime for metastatic HNSCC.

Panitumumab is a fully humanized monoclonal antibody against EGFR receptor. It has a similar mechanism of activity with cetuximab and has shown comparable results to cetuximab in metastatic colon cancer.\textsuperscript{22} It was expected that panitumumab will also show positive results in patients with metastatic HNSCC. But a phase III SPECTRUM trial that compared cisplatin 5FU with or without panitumumab failed to show an OS advantage in the arm containing panitumumab.\textsuperscript{23} Additionally, the panitumumab-based regime had a higher incidence of toxicity also. Only in unplanned subgroup analysis, the benefit of panitumumab was there in p16 negative and oral cavity tumors.

**Case 3**

**A 56-year-old female with a history of tobacco consumption presented with an ulcerated lesion over the buccal mucosa for the last 4 months.** On clinical examination, there was an ulcerated lesion measuring 4 × 4 cm and with matted cervical lymphadenopathy. Biopsy of the lesion revealed squamous cell carcinoma with a combined positive score (CPS) score of 18%. Staging workup revealed multiple lung metastases. Her ECOG PS was 1 and her organ functions were within normal limits. **How to treat the patient?**

IOs have been tried in metastatic HNSCC. For usage of IO in renal cancers and melanoma, no biomarker is required; while for usage in thoracic malignancies, program death ligand (PDL1) staining score is used as an indicator to use IO either as a single agent or in combination with chemotherapy.\textsuperscript{24} PDL1 staining is done on the tumor cells to calculate tumor proportion score (TPS) and various platforms have been used for the same. In HNSCC, instead of TPS scoring a CPS is calculated. In CPS scoring system, intensity is measured not only on the tumor cells but also on the lymphocytes and macrophages. CPS has been found to be a better predictor for response to IO.\textsuperscript{25}

Pembrolizumab, a PD 1 inhibitor, has been approved to be used in the first line of metastatic HNSCC. It can be used either as a single agent or in combination with platinum-based therapy based on the phase III KEYNOTE 048 study.\textsuperscript{26} In this trial, de novo recurrent metastatic HNSCC patients irrespective of PDL1 score were randomized to three arms. They were pembrolizumab monotherapy, pembrolizumab with platinum and 5FU, and cetuximab with platinum and 5FU and the primary endpoint of the trial being OS. It was found that there was an OS advantage with either pembrolizumab alone or pembrolizumab with chemotherapy over...
the cetuximab chemotherapy combination in patients with CPS > 1. However, OS benefit with pembrolizumab and chemotheraphy over cetuximab-based combined therapy was persistent in the whole population irrespective of PDL1 status, but with pembrolizumab monotherapy, the OS was non inferior only to cetuximab arm. The median duration of response was prolonged in both the IO arms. Contrary to the OS advantage, the progression-free survival (PFS) advantage was not there in either the pembrolizumab alone or the combined arm over the chemotherapy. The added OS advantage in spite of inferior PFS was postulated to the alteration of the tumor microenvironment with better sensitivity to subsequent therapy. But this postulation is controversial at present.

The distinction to choose IO alone over combination of IO with chemotherapy in patients with CPS > 1 is not very clear and it is arbitrarily based on the disease burden and symptom complex with pembrolizumab monotherapy is recommended for lesser disease burden with not much symptom complex.

Case 4

A 69-year-old male with a history of tobacco consumption presented with an ulcerated lesion over the gingival sulcus for last 4 months. On clinical examination, there was an ulceroproliferative lesion measuring 5 × 5 cm and with matted cervical lymphadenopathy. Biopsy of the lesion was squamous cell carcinoma. Staging workup revealed multiple lung metastases. His ECOG PS is 2 and he was a coolie with a monthly income of around Rs 1,000 and he could not afford a daycare-based therapy. How to treat the patient?

Treatment of metastatic HNSCC is diverse and it ranges from systemic chemotherapy to monoclonal antibody and recently IOs. The last two options are very expensive in the setting of low middle-income countries like India, leading to less penetration to the patient population. The standard systemic chemotherapy has only shown a modest benefit with associated toxicity. Recently, metronomic therapy has been found to be beneficial in metastatic HNSCC.

Principle of metronomic therapy is repeated administration of selected chemotherapeutic agents at a low dose, which in turn inhibits angiogenesis and also has additional immunomodulatory effects leading to tumor control. Metronomic therapy has found to be beneficial in metastatic HNSCC also. Various agents have been used, most commonly being methotrexate and celecoxib and most were in phase I to II studies. Oral capcitabine has also been used in some cases. Only recently, a phase III study was conducted where metronomic therapy was compared with single-agent cisplatin with the primary objective being OS benefit of metronomic therapy over chemotherapy. Here, patients were randomized to receive either intravenous cisplatin or combination of methotrexate and celecoxib. It was found that median OS in the metronomic arm was superior than the chemotherapy arm (HR: 0.773; 95% CI: 0.65–0.97; p = 0.026) with a better toxicity profile in the metronomic arm. The choice of chemotherapy in the control arm is justifiable as no studies have shown a better OS with doublet chemotherapy over single chemotherapeutic agent.

Case 5

A 60-year-old male presented with history of tobacco consumption presented with an ulcerated lesion over the gingival sulcus for the last 4 months. On clinical examination, there was an ulceroproliferative lesion measuring 5 × 5 cm with matted cervical lymphadenopathy. Biopsy of the lesion revealed squamous cell carcinoma. Staging workup revealed multiple lung metastases. He was treated with a combination of cisplatin and 5FU for a total of 6 cycles. Unfortunately, he developed a progressive disease within 6 months. What are the options to treat the patient?

The choice of second line therapy depends upon the PS of the patient, prior systemic therapy, platinum free interval, and most importantly the financial status. Platinum-free interval (PFI) is defined as the time interval between the last platinum-based therapy to the development of disease progression. The time interval ranges from 3 to 6 months as mentioned in different clinical trials. Those who have a PFI of more than 3 months can be rechallenged with platinum-based therapy. The treatment options are discussed as follows:

A. Systemic chemotherapy

In patients with PFI of more than 6 months, patients can be rechallenged with platinum-based therapy either alone or in combination with doublet-based chemotherapy. Another option is to give low-dose metronomic chemotherapy with methotrexate and celecoxib as it has shown superior survival over cisplatin. Patients who had shorter PFI are deemed to be defined as platinum resistant and carry a poor prognosis. Agents that have been tried are docetaxel and methotrexate. Response rates and OS are very modest and there was no survival advantage over one another.

B. Cetuximab

In patients with no prior exposure to cetuximab and with PFI of more than 6 months, they can be treated with cetuximab along with platinum doublet therapy. Cetuximab has been used either as a single agent or in combination with platinum in patients with shorter PFT in small phase II studies. As a single agent, response rate is around 13% with a median OS of 178 days. Cetuximab has been tried in combination with platinum in a platinum resistant population. The response rates were almost similar to cetuximab monotherapy.

C. Immunotherapy

Before the advent of immunotherapy as a first-line therapy in metastatic HNSCC, they were tried in recurrent second line settings and the results were very encouraging. Both pembrolizumab and nivolumab have received U.S. Food and Drug Administration approval for usage in the second line setting.
Pembrolizumab anti-PD1 inhibitor was compared with nonplatinum agents in platinum resistant cases in KEYNOTE-040 trial. There was an OS advantage in the whole population with pembrolizumab over the controlled arm (HR: 0.8, 0.65–0.98; \( p = 0.016 \)), but mainly in patients with PD-L1 ≥ to 50% (HR: 0.53; 0.35–0.81), the response rates with pembrolizumab were modestly superior than the control arm with lesser incidence of adverse events in the pembrolizumab arm compared with the control arm (13 vs. 36%, respectively). Nivolumab was also used in a similar way in platinum resistant cases in phase III checkmate 141 trial. The primary endpoint was again OS. The trial met its primary in point of improvement of OS from 5.1 to 7.5 months with the use of nivolumab (HR for death, 0.70; 97.73% CI: 0.51–0.96; \( p = 0.01 \)), and the 1-year survival was 36 vs. 16.6%. This trial again established the role of immunotherapy by improving OS in the second line. Durvalumab, an anti PD-L1 inhibitor, has also been tried in recurrent metastatic HNSCC. In a single-arm phase II study, there was a response rate of around 16% with OS of 7.1 months. Durvalumab was compared alone or in combination with tremelimumab with standard systemic therapy in phase III study but it failed to show any benefit over standard systemic therapy.

**EGFR Tyrosine Kinase Inhibitor**

EGFR tyrosine kinase inhibitors like gefitinib and afatinib have been used in platinum resistant settings. Gefitinib

---

**Fig. 1** (A, B) Algorithm regarding first-line treatment in newly diagnosed/platinum-sensitive recurrent metastatic head neck cancer.
did not improve either the response rate or survival compared with single-agent methotrexate.\textsuperscript{37} Afatinib was compared with intravenous methotrexate (40 mg/m\textsuperscript{2}/week) in a phase III randomized trial involving Asian patients who had the disease progression following first-line platinum-based chemotherapy. Out of the 340 randomized patients, afatinib significantly decreased the risk of progression or death by 37\% versus methotrexate (HR: 0.63; 95\% CI: 0.48–0.82; \( p = 0.0005 \); median 2.9 vs. 2.6 months). The response rate was 28\% with afatinib versus 13\% with methotrexate.\textsuperscript{38} Another EGFR tyrosine kinase inhibitor erlotinib has been tried in combination with celecoxib and methotrexate as a metronomic therapy in platinum resistant oral cancers. The 3 month PFS was 71.1\% and the 6 month OS was 61.2\% with a response rate of 43\%.\textsuperscript{39}

E. Newer therapies

The field of recurrent metastatic head and the cancer is evolving fast with newer developments largely based on molecular pathways. Similar pathway is the CDK4/6 pathway. The CDK 4/6 inhibitor palbociclib has been investigated in phase I and II trials. In a phase II trial in combination with cetuximab, the objective response rate was 39\% in the platinum resistant group.\textsuperscript{40,41} Buparlisib 100 mg once daily, a phosphoinositide 3 kinase (PI3K) inhibitor, was combined with paclitaxel versus paclitaxel alone in the phase II randomized BERIL 1 trial. There was an absolute 1.1-month PFS benefit in the combination arm (HR: -0.65; 95\% CI: 0.45–0.95; \( p = 0.01 \)).\textsuperscript{42} Alpelisib is also being studied actively in such patients.\textsuperscript{43} Armamentarium of systemic therapy in metastatic HNSCC has been steadily increased over with the addition of monoclonal antibodies including IO. The response rate and survival advantage is still modest despite being statistically significant. Unfortunately, many of the therapies are still out of the reach for the common people depriving them to get these newer therapies. The therapeutic modality should be tailored and we proposed algorithm as shown in \textsuperscript{\begin{footnotesize} Fig. 1A \& B \end{footnotesize}} respectively.

Case 6

A 25-year-old female from Manipur presented with painless lump over both side of her neck with nasal obstruction since last 3 months. It was neither associated with any fever, cough, night sweats nor any other systemic symptoms. On clinical examination, there was 3 × 4 cm lymph node at right level III and multiple neck nodes max. 3.5 cm in greatest dimension at left level II, III, and IV region. On nasal endoscope, there was mass lesion arising from fossa of Rosenmollar extending right posterior nasal cavity. Biopsy from the mass lesion revealed nonkeratinizing squamous cell carcinoma,
undifferentiated subtype; the tumor cells were positive for p63 and cytokeratin.

Tumor cells are POSITIVE for Epstein–Barr virus encoded RNA (EBER-ISH) consistent with nasopharyngeal primary. Magnetic resonance imaging neck showed 6 × 4.5 cm mass arising from fossa of Rosenmollor with obliteration of left parapharyngeal fat and extending into anterior nasal cavity; without any intracranial extension, enlarged bilateral level II, III, IV, and V cervical nodes maximum dimension 5.2 cm with small right retropharyngeal node. Positron emission tomography computed tomography (PET CT) did not reveal any other metabolically active disease noted elsewhere. After 8 months of completion of her treatment, PET CT showed multiple lung metastasis; she was otherwise fit and symptomatic for her lung metastasis. How to treat the patient?

Nasopharyngeal cancer (NPC) is a malignancy with highly curative potential; skewed geographical distribution and mostly present among younger population with locally advanced stage. Infection with EBV is an important etiological factor particularly in nonkeratinizing and undifferentiated subtype. Workup for NPC should include EBV testing from both tumor and the blood. The method of detection of EBV in tumor includes In situ hybridization (ISH) for EBV encoded RNA (EBER) and IHC staining for LMP1. Real-time polymerase chain reaction is used to evaluate EBV DNA load in plasma or serum and used as a marker for residual diseases monitoring. A meta-analysis showed that pretreatment plasma EBV DNA levels were independent prognostic factors for mortality and distant metastasis. 

Patients with early stage T1N0 M0 NPC should be treated with definitive radiation alone with local control rate around 90%. For loco regionally advanced stage, the Intergroup trial 099 showed highly significant survival advantage favoring combined modality with cisplatin-based chemotherapy and radiation. Asia–specific phase III randomized controlled trails (RCTs) confirmed that 5 years OS was around 70% for the chemoradiation compared with RT alone. Subsequently, an individual patient-based meta-analysis of eight RCTs showed an absolute benefit in OS and EFS at 5 years with highest benefit resulting from concomitant chemoradiation rather than neoadjuvant or adjuvant chemotherapy. A network meta-analysis (including 20 trials and 5,144 patient) showed that addition of adjuvant chemotherapy to chemoradiation was associated with better PFS compared with chemoradiation alone.

Meta-analysis established the role of induction chemotherapy followed by chemoradiation is another standard of care in node-positive diseases. Gemcitabine and cisplatin are preferred induction regimen, whereas for EBV-associated diseases modified TPF (docetaxel 60 mg/m², cisplatin 60 mg/m², 5FU 600 mg/m² CI for 5 days) is preferred regimen. A network meta-analysis (including 20 trials and 5,144 patient) showed that addition of adjuvant chemotherapy to chemoradiation was associated with better PFS compared with chemoradiation alone. For metastatic NPC, there is limited options for systemic therapy and enrolment in a clinical trials is preferred. Gemcitabine plus cisplatin is the preferred first-line chemotherapy regimen demonstrated survival advantage compared with Cisplatin plus 5FU. The role of cetuximab in combination with platinum salts tested in a phase II trial with acceptable safety profile in heavily pretreated patients. The role immune checkpoint inhibitors like pembrolizumab (KEYNOTE-028) and nivolumab (NCI 9742) were tested in phase I/II trials, but the results were not so encouraging.

Conflict of Interest

None.

References


